Notes

A news scan found the headline 'ROIV 2022–24 ROIV/SPY daily regression'. Measured on September 7, the analysis used all-adjusted IEX daily bars from January 1, 2022, through September 4, 2026. The source of the data is a partial venue, not the National Best Bid and Offer, which is a system that provides the best available prices for buying and selling securities. The results of the analysis are as follows: the number of data points is 752, the correlation is 0.3235481320645487, the daily alpha percentage is 0.04913680336813414, the beta is 1.0984286641213996, the R-squared value is 0.10468339376245828, the daily mean percentage is 0.09205034536191495, the daily standard deviation percentage is 3.7338486933286776, the minimum percentage is -12.939698492462314, and the maximum percentage is 22.28163992869876. https://runway.adityaperswal.workers.dev/data/stock-bars

A news scan found the headline is not available, but a data line was found with the following information: Measured on September 7, the technical state of IEX was analyzed using all-adjusted daily bars from January 1, 2022, through September 4, 2026. The source of this data is a partial venue, not the National Best Bid and Offer, which is a system that provides the best available bid and ask prices for a security. The data includes 1173 bars, with the first bar on January 3, 2022, at 00:00:00, and the last bar on September 4, 2026, at 00:00:00. The close price was 34.945, and other technical indicators were also calculated, including a 10-day simple moving average of 35.454, a 20-day simple moving average of 35.91775, a 50-day simple moving average of 35.2768, an average true range of 1.1575 over 14 days, an average daily range of 1.12 over 14 days, a low price of 33.43 over 20 days, a high price of 37.92 over 20 days, a volume percentage of 35.02594834205775 over 20 days, an average volume of 350422.75 over 20 days, and a return percentage of -3.7725457799807183 over 20 days. https://runway.adityaperswal.workers.dev/data/stock-bars

A news scan found the headline 'Sep7readback:48lastRun06:30:53.373Z,length1590,threefilingchecks,twoGISreminders,END;next10:30:53.373Z. Jobs30lastSep6 20:45,next08:45;33last05:15,next09:15;27last05:15,next13:15;17last02:30,nextSep8 02:30. Completiondoesnotproveexhaustivesurveillance.' This is a raw script output. runway:list_jobs?fund=catalyst

A news scan found the calendar for September 7 in HTML format, which returned headers without rows. Searches for an exact date found comment deadlines, public meetings, and clinical readouts, but not a confirmed drug decision for September 8 or 9. This lack of information does not necessarily mean that a decision was not made. The closest upcoming event to watch is TLX on September 11 from the issuer, and it is still possible that early decisions could be made. https://www.fda.gov/advisory-committees/advisory-committee-calendar

A news scan found the headline 'Issuer index re-read on September 7, latest visible BiPAS enrollment pathway notice; no Pixclara action seen in returned latest page.' This is not an exhaustive or proof of no decision; the September 11 deadline remains prior to primary verification. https://telixpharma.com/news-views/

A news scan found the headline that the next STEO release is on September 9. An agency re-read on September 7 stated that the next STEO release is on September 9, and the prior release was on August 11, which was forecasted to be completed on August 6. The release hour has not been verified. https://www.eia.gov/outlooks/steo/outlook.php

A review of the agency calendar on September 7 found that the G19 Consumer Credit report is scheduled for release on September 8 at 15:00 ET. The September 7 holiday caused a shift in the daily and weekly releases to September 8. The publication calendar provides the date and time of the release, but does not provide the new value. https://www.federalreserve.gov/newsevents/2026-september.htm

A calendar from an agency was reviewed on September 7. It showed that on September 8 at 10 ET, there will be releases of data on manufacturing, mining, wholesale, selected services, and retail for the second quarter. On September 9 at 10 ET, there will be a release of the Quarterly Services Survey for the second quarter. https://www.census.gov/economic-indicators/calendar-listview.html

A calendar was last modified on February 18 and reviewed again on September 7. It shows that the June 2026 ECEC will be on September 9 at 10 ET, and the August PPI will be on September 10 at 08:30 ET, and the CPI will be on September 11 at 08:30 ET, which are all outside of the next two sessions. Note that ECEC is a separate measure from the Employment Cost Index or the Consumer Price Index. https://www.bls.gov/schedule/2026/09_sched.htm

A news scan found the headline that on September 2, the issuer confirms that on September 9 at 8:00 ET, the OPGBEST1 Phase 1/2 cohort 1 topline results will be presented in a clinical webcast. The full clinical data set and additional analyses will be presented at later meetings. It is noted that one should not infer complete evidence from the topline results. https://ir.opusgtx.com/press-releases/detail/542/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences

A news scan found the headline that on September 4, the issuer confirms that on September 8, at 5:00 PM Pacific Time, which is 8:00 PM Eastern Time, there will be a webcast to discuss the primary endpoint results of the Phase 2 trial of INBRX-106 for first-line head and neck squamous cell carcinoma, which may not be the first news about this topic. https://inhibrx.investorroom.com/2026-09-04-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Primary-Endpoint-Results-for-INBRX-106-Phase-2-First-Line-HNSCC-Study

A news scan found the headline about the ITX.MC September 9 half-year date-only agenda. The issuer's agenda was re-read on September 7, 2026, for the interim half year on September 9, with no release hour specified. The eligibility for non-US, foreign exchange, and venue remains unvalidated. https://www.inditex.com/itxcomweb/es/en/investors/finance

A news scan found the headline that on August 26, the issuer confirmed that the second quarter earnings for ASO will be released on September 9 before the market opens. A prior journal entry mentioned a 10 ET conference call. The exact minute of the first release is unknown. The information was re-read on September 7. https://investors.academy.com/news-releases/news-release-details/academy-sports-outdoors-announces-second-quarter-fiscal-2026

A news scan found the headline that on August 25, the issuer confirmed that the third quarter, which ended on July 30, would have its release on September 8 after the market close, with a 17 Eastern Time call. The collector for September 9 at 12:30 UTC is chosen for the next day review, not the actual earnings date. A note to re-read the information from September 7 was also found. https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial

A news scan found the headline about GameStop Corporation, ticker symbol GME, with a preannouncement of its financial results for the 13 weeks ended on August 1. The complete results are expected to be released on September 8, but the exact hour of release is not specified. The expected sales are between 780 million and 800 million dollars, operating income is between 150 million and 170 million dollars, and net income is between 290 million and 310 million dollars. The company also expects to have between 5050 million and 5070 million dollars in cash and securities. The net income includes approximately 238 million dollars in gains from eBay and approximately 75 million dollars in losses from digital assets, which is a type of investment. The source of this information has already made this announcement, so when the complete results are released on September 8, it should not be considered new or surprising information. https://investor.gamestop.com/news-releases/news-details/2026/GameStop-Announces-Second-Quarter-2026-Preliminary-Results/default.aspx

A search result from September 7 confirms that the issuer, Casey's, will release its Q1 FY 2027 earnings on September 8 after the market closes. The original document can be found at https://investor.caseys.com/node/17571/pdf, but it was not accessible on this run, returning a 403 error. A prior journal entry has a direct link to the PDF. This search result provides a partial verification, but it does not involve re-reading the full PDF. https://investor.caseys.com/press-releases

A news scan found the headline about UNFI's September 8 earnings session. The issuer announced a morning call on September 8 at 8:30 ET to discuss the 13-week fourth quarter and 52-week fiscal year that ended on August 1. The exact minute of the first release was not specified. The information was re-read on September 7. https://ir.unfi.com/news/press-release-details/2026/United-Natural-Foods-to-Release-Fourth-Quarter-and-Full-Year-Fiscal-2026-Results-on-September-8-2026/default.aspx

A news scan found the headline that on August 25, the issuer announced that the Q3 FY2026 earnings call will be held before the market opens on September 8 at 08:30 ET. It is noted that the first minute of the release is not promised, and investors are advised to re-read the information on September 7. https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results

On September 6 at 01 EDT, the issuer released a notice stating that on September 8, there will be an ERS presentation at 12:15 CEST, which is equivalent to 06:15 ET or 10:15 UTC, and an investor call at 08 ET, which is equivalent to 12 UTC. The exact earliest public data release may happen before the presentation, so do not plan to exit based on the later investor call. This event is about the Phase 2 clinical readout, which is not the same as an FDA decision, a government agency that approves drugs, known as the Food and Drug Administration. https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat